Category: "Stocks To Watch"

First Bancshares is a company on a high growth trajectory and with inclusion on the Russell 2000 index for the first time. The company has made some strategic acquisitions and mergers over the last year and is growing EPS and revenue nicely. The company just reported earnings and revenue beats on July 21, 2017.

Good old Doc Copper with his Ph.D in forecasting the growth of the global economy is getting more bullish over the last few months.

The Pennsylvania Real Estate Investment Trust is looking surprisingly strong with a pocket pivot signal on rising large players volume.

A big horizontal breakout and rising large players volume suggests a lot of people with a lot of money are buying this stock. CKO Kickboxing will now be offered at Madison Square Garden. Owning this stock is like owning a little bit of various sporting teams. I'm going to go running with the Bulls in this stock and chase it higher on the channel breakout.

Everyone is going crazy about this article I wrote on Cellectis. I've got comments from people telling me to mortgage my house and park a truck-load of money into this company. Calm down everyone. Cellectis is years away from and kind of FDA approval of their UCAR T-cell therapy. There's plenty of time to be calm and not chase this stock higher.

Quality large cap stocks are the name of the game in the Ishares MSCI USA Quality Factor ETF. In some ways this is the ultimate monopoly ETF that you can play on the increasing consolidation across major technology companies. If Republicans get their way, the government is not going to be breaking up these monopolies in the next 4 years and so big money is moving into these corporations.

More bank stocks than ever are looking like compelling trades. Everything changed for banks after the stress tests a few weeks ago and the Federal Reserve allowing banks to increase share buybacks and dividends.

Financial stocks and in particular banking stocks, are looking stronger. You have raising rates, less regulations, and increase in share buybacks and dividends that are all acting as a tail-wind for banking stocks.

Novartis is going to be the first company to get FDA approval on a CAR T therapy. The actual FDA approval is likely to come by October 2017. Novartis is running with the lead CAR T therapy pack in this exciting new medicine that opens up a whole new way of battling cancer.